Better diagnosis, David Botstein
Interviewee: David Botstein. David Botstein talks about the goal of using microarray analysis to improve cancer diagnosis. (DNAi Location: Applications > Genes and medicine > Genetic profiling > David Botstein > Better diagnosis)
You can imagine that we can identify proteins that, on the basis of over expression of their RNA, which is what we measure, that might be detected in the circulation when people have cancer and yet, as yet don't have symptoms. And it is a longer term goal of ours to make that into a reality. There's every theoretical reason for believing that that can be done and there are examples that already exist, for example the PSA for prostate cancer is such a test. And it's enormously valuable in the management of the disease.
david botstein,cancer proteins,cancer diagnosis,genetic profiling,theoretical reason,location applications,dnai,gene expression,prostate cancer,interviewee,term goal,rna,psa,genes,circulation,medicine
David Botstein discusses how identifying the molecular mechanisms of cancer will lead to the development of improved therapies.
David Botstein (sitting with Pat Brown) talks about how innovations in genomics might lead to personalized medicine.
David Botstein talks about how tumor typing using genome-wide analysis will help doctors determine the most appropriate treatments for their patients.
Pat Brown talks about using microarrays to discover the differences between cancer cells and healthy cells.
Stephen Fodor talks about how an individual's gene expression profile can help determine what therapies might work best.
Mark Skolnick talks about forming a company to discover genes and develop genetic tests.
Mark Skolnick talks about taking advantage of the well-documented genealogy of the Mormon pioneers to study inherited genetic disorders.
Mary-Claire King talks about the value of using the centuries-old tool of family pedigrees to gain insight into patterns of inheritance of genetic disorders.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Mary-Claire King reflects on how knowledge gained from the identification of BRCA1 and BRCA2 could lead to improved cancer treatments.